Browsing by Author Phillips T.J.
Showing results 1 to 8 of 8
| Preview | Issue Date | Title | Author(s) |
|---|---|---|---|
| 6-Aug-2021 | Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response. | Salles G.; Tilly H.; Chaidos A.; McKay P.; Phillips T.J.; Assouline S.E.; Batlevi C.L.; Campbell P.; Ribrag V.; Damaj G.L.; Dickinson M.; Jurczak W.; Kazmierczak M.; Opat S. ; Radford J.A.; Schmitt A.; Whalen J.; Hamlett A.; Kamp B.; Adib D.; Morschhauser F. | |
| 17-Oct-2023 | Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. | Song Y.; Zhou K.; Zou D.; Li D.; Hu J.; Yang H.; Zhang H.; Ji J.; Xu W.; Jin J.; Lv F.; Feng R.; Gao S.; Zhou D.; Tam C.S.; Simpson D.; Wang M.; Phillips T.J.; Opat S. ; Fang C.; Sun S.; Zhu J. | |
| 23-Nov-2023 | Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis. | Song Y.; Zhou K.; Zou D.; Li D.; Hu J.; Yang H.; Zhang H.; Ji J.; Xu W.; Jin J.; Lv F.; Feng R.; Gao S.; Zhou D.; Tam C.S.; Simpson D.; Wang M.L.; Phillips T.J.; Opat S. ; Fang C.; Sun S.; Zhu J. | |
| 30-Jul-2020 | Outcomes of relapsed/refractory MCL patients treated with zanubrutinib monotherapy in the second line and in later lines: A pooled analysis from 2 studies. | Phillips T.J.; Simpson D.; Wang M.; Opat S. ; Song Y.; Huang Z.; Lu H.; Zhou K.; Zou D.; Zhou J.; Hu J.; Yang H.; Zhang H.; Ji J.; Xu W.; Jin J.; Lv F.; Feng R.; Gao S.; Zhou D.; Tam C.S. | |
| 1-Mar-2019 | Updated safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma. | Huang J.; Hilger J.; Novotny W.; Trotman J.; Tam C.S.; Wang M.; Simpson D.; Opat S. ; Cull G.; Munoz J.; Phillips T.J.; Kim W.-S. | |
| 13-Aug-2019 | Updated safety and efficacy data in the phase 1 trial of patients with mantle cell lymphoma (MCL) treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111). | Wei R.; Atwal S.; Huang J.; Trotman J.; Elstrom R.; Tam C.S.; Wang M.; Simpson D.; Opat S. ; Cull G.; Munoz J.; Phillips T.J.; Kim W. | |
| 17-Dec-2021 | Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. | Tam C.S.; Opat S. ; Simpson D.; Cull G.; Munoz J.; Phillips T.J.; Kim W.S.; Rule S.; Atwal S.K.; Wei R.; Novotny W.; Huang J.; Wang M.; Trotman J. | |
| 4-May-2022 | Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. | Zhou K.; Zou D.; Zhou J.; Hu J.; Yang H.; Zhang H.; Ji J.; Xu W.; Jin J.; Lv F.; Feng R.; Gao S.; Zhou D.; Tam C.S.; Simpson D.; Wang M.; Phillips T.J.; Opat S. ; Huang Z.; Lu H.; Song Y. |